KORU Medical Systems, Inc.
NASDAQ:KRMDMedical - Instruments & Supplies
+$0.06 today
- Market cap
- $149.64M
- Beta
- 0.42
- P/E (TTM)
- -80.2
- EPS (TTM)
- -$0.05
Volume 0.19M
Average 0.13M
KRMD Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
KORU Medical Systems, Inc.NASDAQ: KRMD
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue grows in line with its trailing trend
Q1 FY2026 revenue of $11.76M rose 22.1% year over year, behind the +23.3% change in trailing-twelve-month revenue. Sequentially, it rose 8.0% from the prior quarter. Over 3 fiscal years it compounded at +13.8% a year.
Context
- Revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $48.22M (+17.2%) for the fiscal year ending Dec 2026, a slowdown from the +22.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $11.76M+8.0% QoQ
- Last fiscal yearDec 2025
- $41.13M+22.2% YoY
- LTMMar 2026
- $43.26M+23.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +22.1% | +14.0% | -8.1 pp |
| 1 year | +22.2% | +17.2% | -5.0 pp |
| 3-year CAGR | +13.8% | +16.4% | +2.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 41.13M USD
- Year-over-year change
- +22.2%
- 4-year CAGR
- +15.0%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 41.13M | +22.2% |
| FY2024 | 2024-12-31 | 33.65M | +18.0% |
| FY2023 | 2023-12-31 | 28.52M | +2.2% |
| FY2022 | 2022-12-31 | 27.9M | +18.8% |
| FY2021 | 2021-12-31 | 23.49M | — |
Revenue vs competitors
How KRMD compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +23.3% is the 6th highest of 10, against a peer median of +34.8%.
- Over three fiscal years its annual growth of +13.8% compares with a peer median of +31.8%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $151.64M USD | +69.5% | +31.8% | |
| LTM Mar 2026 | $142.4M USD | +3.5% | +9.3% | |
| LTM Mar 2026 | $113.75M USD | +174.0% | +91.5% | |
| LTM Mar 2026 | $113.02M USD | -30.1% | -33.3% | |
| LTM Mar 2026 | $44.88M USD | +39.6% | +53.9% | |
| LTM Mar 2026 | $43.26M USD | +23.3% | +13.8% | |
| LTM Mar 2026 | $37.53M USD | -4.4% | -9.7% | |
| LTM Mar 2026 | $32.29M USD | -14.3% | -9.3% | |
| LTM Mar 2026 | $18.87M USD | +34.8% | +34.8% | |
| LTM Mar 2026 | €16.32M EUR | +273.9% | +48.1% | |
| Peer median (excluding KRMD) | — | +34.8% | +31.8% | |
Competitors are the stored peer set for KRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 23.49M | 27.9M | 28.52M | 33.65M | 41.13M |
| Cost of Revenue | 9.72M | 12.53M | 11.81M | 12.31M | 15.52M |
| Gross Profit | 13.77M | 15.37M | 16.71M | 21.33M | 25.6M |
| Gross Margin | 58.6% | 55.1% | 58.6% | 63.4% | 62.3% |
| Research & Development | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M |
| Selling, General & Admin | 0 | 0 | 0 | 0 | 23.38M |
| Operating Expenses | 20.8M | 26.15M | 26.98M | 27.78M | 28.58M |
| Depreciation & Amortization | 463.13K | 587.14K | 870.39K | 772.89K | 810.5K |
| EBITDA | (5.9M) | (10.09M) | (8.9M) | (5.29M) | (1.81M) |
| EBITDA Margin | -25.1% | -36.2% | -31.2% | -15.7% | -4.4% |
| Operating Income | (7.03M) | (10.78M) | (10.27M) | (6.45M) | (2.97M) |
| Operating Margin | -29.9% | -38.6% | -36.0% | -19.2% | -7.2% |
| Interest Income | 13.08K | 145.59K | 561.33K | 444.64K | 293.4K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 665.09K | 105.71K | 496.4K | 382.49K | 356.41K |
| Income Before Tax | (6.36M) | (10.68M) | (9.77M) | (6.06M) | (2.62M) |
| Pre-Tax Margin | -27.1% | -38.3% | -34.3% | -18.0% | -6.4% |
| Income Tax Expense | (1.8M) | (2.01M) | 3.97M | 2.89K | 21.89K |
| Net Income | (4.56M) | (8.66M) | (13.74M) | (6.07M) | (2.64M) |
| Net Margin | -19.4% | -31.0% | -48.2% | -18.0% | -6.4% |
| EPS (Basic) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| EPS (Diluted) | (0.10) | (0.19) | (0.30) | (0.13) | (0.06) |
| Weighted Avg Shares | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
| Weighted Avg Shares (Diluted) | 44.39M | 45M | 45.6M | 45.8M | 46.19M |
KORU Medical Systems, Inc.
NASDAQ:KRMD
Intrinsic Alpha fair value
Locked
Current Price
$3.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.